Cortechs.ai | Cortechs.ai appoints Dr. Chris Airriess as new CEO

Cortechs.ai appoints Dr. Chris Airriess as new CEO

Industry veteran, Amy Verrinder, named VP of Sales 

(SAN DIEGO) Sept. 1, 2019 — Cortechs.ai is pleased to announce the appointments of its new chief executive officer, Dr. Chris Airriess, and vice president of sales, Amy Verrinder. Both executives have been long-time employees of Cortechs.ai and have contributed fundamentally to the company’s growth.

Dr. Airriess has been part of the Cortechs.ai team for over 12 years, serving as the company’s chief technology officer and chief operating officer. He was a major catalyst in the development of the flagship product, NeuroQuant®, and came to Cortechs.ai with a wealth of experience guiding product and company development.

Before joining Cortechs.ai, Dr. Airriess oversaw the development and growth of therapeutics designed to combat metastatic melanoma and neuromuscular disorders as the chief operating officer for California Stem Cell. He has also served as a director of scientific computing for the Biomedical Informatics Research Network, headquartered at the University of California San Diego. His past leadership roles and extensive technical background make Dr. Airriess a key driver of the growth and expansion of Cortechs.ai.

Amy Verrinder has over 25 years of experience in business development and has been a strong leader in educating clinicians, researchers and business professionals about the power of volumetric imaging. She previously served as Cortechs.ai’ director of sales and national sales director prior to her appointment as vice president of sales. Amy has brought the workflow enhancements and patient outcome improvements, offered by Cortechs.ai’ suite of products, to dozens of major hospitals and independent imaging facilities across the country. Her deep knowledge of the healthcare industry has allowed her to form strong relationships with stakeholders across North America.

Cortechs.ai has several new initiatives for the remainder of 2019 and beyond. Dr. Airriess and Amy Verrinder both look forward to building upon current momentum as the company continues to deploy innovative solutions to aid in the diagnosis of neurodegenerative diseases and, most importantly, to better patient care.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.

###

More Resources

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”

07/16/2025

Advancing Prostate MRI with Restriction Spectrum Imaging

Why is OnQ Prostate unique, and what makes it a game-changer for clinicians?

07/08/2025

Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroAlign CT

Time-sensitive and precise diagnostic imaging can mean the difference between rapid intervention and devastating outcomes.
Scroll to Top